These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27065108)

  • 41. Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA.
    Rakhmanina N; Lam KS; Hern J; Young HA; Walters A; Castel AD
    J Int AIDS Soc; 2016; 19(1):20936. PubMed ID: 27797320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying Spatial Variation Along the HIV Care Continuum: The Role of Distance to Care on Retention and Viral Suppression.
    Terzian AS; Younes N; Greenberg AE; Opoku J; Hubbard J; Happ LP; Kumar P; Jones RR; Castel AD;
    AIDS Behav; 2018 Sep; 22(9):3009-3023. PubMed ID: 29603112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study.
    Dragovic G; Smith CJ; Jevtovic D; Dimitrijevic B; Kusic J; Youle M; Johnson MA
    BMC Infect Dis; 2016 Mar; 16():106. PubMed ID: 26939611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study.
    Tripathi A; Youmans E; Gibson JJ; Duffus WA
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):751-8. PubMed ID: 21142607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients.
    Chow WZ; Lim SH; Ong LY; Yong YK; Takebe Y; Kamarulzaman A; Tee KK
    PLoS One; 2015; 10(9):e0137281. PubMed ID: 26335136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
    Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
    Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
    Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
    Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human immunodeficiency virus transmission at each step of the care continuum in the United States.
    Skarbinski J; Rosenberg E; Paz-Bailey G; Hall HI; Rose CE; Viall AH; Fagan JL; Lansky A; Mermin JH
    JAMA Intern Med; 2015 Apr; 175(4):588-96. PubMed ID: 25706928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study.
    Kayigamba FR; Franke MF; Bakker MI; Rodriguez CA; Bagiruwigize E; Wit FW; Rich ML; Schim van der Loeff MF
    PLoS One; 2016; 11(7):e0159446. PubMed ID: 27438000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cascade of care for people living with HIV infection in Southern Brazil: results from a public health network.
    Vogler IH; Alfieri DF; Gianjacomo HDB; Almeida ERD; Reiche EMV
    Cad Saude Publica; 2018 Nov; 34(12):e00009718. PubMed ID: 30517309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Continuous Retention and Viral Suppression Provide Further Insights Into the HIV Care Continuum Compared to the Cross-sectional HIV Care Cascade.
    Colasanti J; Kelly J; Pennisi E; Hu YJ; Root C; Hughes D; Del Rio C; Armstrong WS
    Clin Infect Dis; 2016 Mar; 62(5):648-654. PubMed ID: 26567263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poor retention in care one-year after viral suppression: a significant predictor of viral rebound.
    Crawford TN
    AIDS Care; 2014; 26(11):1393-9. PubMed ID: 24848440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of virological response to antiretroviral therapy: socio-economic status still plays a role in the era of cART. Results from the ANRS-VESPA 2 study, France.
    D'Almeida KW; Lert F; Spire B; Dray-Spira R
    Antivir Ther; 2016; 21(8):661-670. PubMed ID: 27355137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up.
    Lin KY; Cheng CY; Li CW; Yang CJ; Tsai MS; Liu CE; Lee YT; Tang HJ; Wang NC; Lin TY; Lee YC; Lin SP; Huang YS; Zhang JY; Ko WC; Cheng SH; Hung CC;
    PLoS One; 2017; 12(6):e0179870. PubMed ID: 28665938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
    Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
    J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimating HIV transmissions in a large U.S. clinic-based sample: effects of time and syndemic conditions.
    Satyanarayana S; Safren SA; Rogers BG; Bainter SA; Christopoulos KA; Fredericksen RJ; Mathews WC; Moore RD; Mugavero MJ; Napravnik S; Carrico AW; Mimiaga MJ; Mayer KH; Crane HM
    J Int AIDS Soc; 2021 Mar; 24(3):e25679. PubMed ID: 33724718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.